AstraZeneca announces positive results for lupus drug from clinical trial

  • Tue 12 Nov 2019 07:35

    AstraZeneca said its lupus drug had shown superior results compared with a placebo in a clinical trial.

    On the primary endpoint, anifrolumab achieved meaningfully reduced disease activity at week 52, with 47.8% of patients receiving the drug responding compared with 31.5% of patients on placebo, the drugmaker said.

    'There has only been one new medicine approved for systemic lupus erythematosus in the last 60 years, which is why we are so excited to see the positive TULIP 2 results,' said Mene Pangalos, executive vice president, BioPharmaceuticals R&D.

    'There is now a strong body of evidence demonstrating the benefit of anifrolumab, and we look forward to bringing this potential new medicine to patients with systemic lupus erythematosus as soon as possible,' Pangalos added.

<< Back <<

AstraZeneca (AZN)

7,350.00p +44.00p (+0.60%) delayed 05:00AM
Price delayed by 15 minutes.